Risks of reformulation: French patients complain after Merck modifies levothyroxine pills
Abstract
Huge rises in side effects have led to protests and legal charges, reports Barbara Casassus
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In March 2017, the removal of lactose and the addition of mannitol and citric acid to the new formulation of LT4 from Merck resulted in complaints from 67% of the 1745 patients.
“In March 2017, the removal of lactose and the addition of mannitol and citric acid to the new formulation of LT4 from Merck resulted in complaints from 67% of the 1745 patients (116).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [116]
Cites
Thyroxine: anatomy of a health scare
Faasse, K., Cundy, T., & Petrie, K. J. (2009) · BMJ · doi:10.1136/bmj.b5613 · Cited by 72 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Levothyroxine: conventional and novel drug delivery formulations.
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac030 · Cited by 63 · see citing works
Impact of a forced dose-equivalent levothyroxine brand switch on plasma thyrotropin: a cohort study.
Flinterman, L. E., Kuiper, J. G., Korevaar, J. C., van Dijk, L., Hek, K., Houben, E., Herings, R., Franken, A. A. M., de Graaf, J. P., Horikx, A., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0414 · Cited by 23 · see citing works
Levothyroxine sodium pentahydrate tablets – formulation considerations
Kaur, N., & Suryanarayanan, R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.006 · Cited by 19 · see citing works
- Authors
- Casassus, B.
- Corresponding author
- Casassus, Barbara
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2018-02-16
- Volume
- 360
- Pages
- k714
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2791924017
- Cited by
- 23
- References
- 1
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 5
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-02-23)
- Open access
- closed
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- levothyroxine, drug reformulation, adverse drug reactions, patient complaints, pharmaceutical litigation, thyroid hormone replacement, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
